

# Use of Nonclonal Serum Immunoglobulin Free Light Chains to Predict Overall Survival in the General Population

Angela Dispenzieri, MD; Jerry A. Katzmann, PhD; Robert A. Kyle, MD;  
Dirk R. Larson, MS; Terry M. Therneau, PhD; Colin L. Colby; Raynell J. Clark;  
Graham P. Mead, BSc, PhD; Shaji Kumar, MD; L. Joseph Melton III, MD;  
and S. Vincent Rajkumar, MD

## Abstract

**Objective:** To determine whether the free light chain (FLC) assay provides prognostic information relevant to the general population.

**Methods:** After excluding persons with a known plasma cell disorder, we studied 15,859 Olmsted County, Minnesota, residents 50 years or older in whom unmasked data and samples for FLC testing were available. Baseline information was obtained between March 13, 1995, and November 21, 2003, and follow-up status and cause of death were identified through June 30, 2009. The  $\kappa$  and  $\lambda$  FLC sum ( $\Sigma$  FLC) was evaluated for its ability to predict overall survival. Specific causes of death were also investigated.

**Results:** In 158,003 person-years of follow-up, 4348 individuals died. A high  $\Sigma$  FLC was significantly predictive of worse overall survival; the risk ratio for death for those with the highest decile of  $\Sigma$  FLC (ie,  $\geq 4.72$  mg/dL) was 4.4 (95% confidence interval, 4.1-4.7) relative to the remaining study participants. Multivariate analyses demonstrated that this excess risk of death was independent of age, sex, and renal insufficiency, with a corrected risk ratio of 2.1 (95% confidence interval, 1.9-2.2). The increased mortality was not restricted to any particular cause of death because the observed-to-expected risk of death from most causes was significantly higher among those individuals with an antecedent  $\Sigma$  FLC of 4.72 mg/dL or higher, which is near the upper limit of normal for the test.

**Conclusion:** A nonclonal elevation of  $\Sigma$  FLC is a significant predictor of worse overall survival in the general population of persons without plasma cell disorders.

© 2012 Mayo Foundation for Medical Education and Research ■ Mayo Clin Proc. 2012;87(6):517-523

The serum immunoglobulin free light chain (FLC) assay has been important in the management of plasma cell disorders, such as monoclonal gammopathy of undetermined significance (MGUS), multiple myeloma, and amyloidosis, with respect to diagnosis, prognosis, and disease measurement.<sup>1</sup> Additional uses for the assay include the identification of a premalignant condition called light chain MGUS (LC-MGUS)<sup>2</sup> and prognostication in other hematologic conditions, such as chronic lymphocytic leukemia<sup>3,4</sup> and non-Hodgkin lymphoma.<sup>5</sup> When screening for clonal disease, the  $\kappa$ -to- $\lambda$  FLC ratio (rFLC) is used to correct for both impaired catabolism (renal function) and nonspecific production (generalized immune overstimulation). This adjustment makes it possible to identify patients with a relative imbalance between  $\kappa$  and  $\lambda$  concentrations, which typically qualifies for clonal excess. Investigators have also used the absolute value of an involved FLC for various end points.<sup>5,6</sup> Presumably by acting as a global marker of immune stimulation, nonclonal elevations of FLCs represent

a risk of developing non-Hodgkin lymphoma among patients with human immunodeficiency virus infection<sup>7</sup> and of short event-free survival among patients with diffuse large cell lymphoma.<sup>5</sup> The purpose of the present study was to test the hypothesis that nonclonal elevation of serum FLCs, measured as the serum  $\kappa$  and  $\lambda$  FLC sum ( $\Sigma$  FLC), is a significant predictor of overall survival in the general population.

## METHODS

This study was performed in accordance with the Declaration of Helsinki and with approval of the Mayo Clinic Institutional Review Board and the Olmsted Medical Group. The Olmsted County MGUS prevalence cohort was composed of 21,462 of the 28,038 enumerated individuals 50 years and older who were living in Olmsted County, Minnesota, between January 1, 1995, and November 21, 2003.<sup>8</sup> Because it captured more than 75% of the resident population in this age range, the cohort is considered to be representative of the general population



For editorial  
comment, see  
page 505

From the Division of Hematology (A.D., R.A.K., S.K., S.V.R.), Department of Laboratory Medicine (A.D., J.A.K., R.J.C.), Division of Biomedical Statistics and Informatics (D.R.L., T.M.T., C.L.C.), and Division of Epidemiology (L.J.M.), Mayo Clinic, Rochester, MN; and the Division of Infection and Immunity, University of Birmingham, Birmingham, England (G.P.M.).

living in a defined geographic area. Of the total 21,462 individuals in the cohort, we excluded 710 persons with known plasma cell disorders, including those with MGUS and LC-MGUS, because they represent conditions in which clonal elevations of FLCs occur and in which the prognostic value of increased FLCs is well established.<sup>2,9</sup> A relatively newly described entity, LC-MGUS is defined as the presence of an abnormal rFLC with an elevation in at least one of the FLCs.<sup>2</sup> We also excluded 4096 individuals who declined to provide authorization to participate in research,<sup>10</sup> 758 with an inadequate sample to perform the FLC assay, and 39 whose cause of death was recorded using a coding scheme other than that in the *International Classification of Diseases, Ninth Revision (ICD-9)* or *International Statistical Classification of Diseases, 10th Revision (ICD-10)* format. Thus, the final study cohort for the primary analyses to determine the prognostic value of nonclonal FLC elevation on overall survival comprised 15,859 individuals. Baseline information was obtained for these individuals between March 13, 1995, and November 21, 2003, and follow-up status and cause of death information were identified through June 30, 2009. For the multivariate analyses, 2772 additional individuals were excluded be-


cause of lack of a coincident serum creatinine measurement. Individuals were followed up using the data resources of the Rochester Epidemiology Project.<sup>11,12</sup> Deaths and causes of death were ascertained using death certificate ICD-9 and ICD-10 codes. All codes were converted to ICD-10 (<http://www.cdc.gov/nchs/icd/icd10cm.htm>) and analyzed at the chapter level.<sup>9</sup>

Measurements were performed using the FLC assay (Binding Site, Birmingham, England). The reference ranges for  $\kappa$  FLCs and  $\lambda$  FLCs are 0.33 to 1.94 mg/dL and 0.57 to 2.63 mg/dL (to convert to mg/L, multiply by 10), respectively, and the reference range for the rFLC is 0.26 to 1.65.<sup>13</sup> To calculate the reference range for the  $\Sigma$  FLC, we used  $\kappa$  FLC and  $\lambda$  FLC concentrations from the original reference range study<sup>13</sup> and estimated standard errors of the quantile regression parameters using a bootstrap resampling procedure with replacement in 10,000 replicates.<sup>14</sup> The resulting overall 95% reference range was 0.93 to 4.33 mg/dL. The  $\Sigma$  FLC was significantly associated with age at the 95th percentile ( $P < .001$ ) but not at the 25th percentile. The association of  $\Sigma$  FLC with age disappeared when the FLC concentrations were normalized by cystatin C concentrations.<sup>13</sup> Because the  $\Sigma$  FLC increased at 65 years of age, the age-specific reference ranges were 0.72 to 3.55 mg/dL among individuals 65 years or younger and 1.35 to 5.95 mg/dL among individuals older than 65 years (J.A.K., personal communication).


Survival time was calculated from the time of sample ascertainment using the method of Kaplan and Meier, and differences in survival were assessed using log-rank tests. The adjusted curves are based on a direct adjusted survival estimate.<sup>15</sup> The risk of death (risk ratio) associated with  $\Sigma$  FLC, creatinine, age, and sex was estimated using both univariate and multivariate Cox proportional hazards models. In these models, age (per 10 years) and serum creatinine (per 1-mg/dL unit) were incorporated as continuous variables. The individuals in the Olmsted research cohort were further classified according to whether they had a  $\Sigma$  FLC in the top decile ( $\geq 4.72$  mg/dL) or not, and the risk of death was calculated as a standardized mortality ratio (observed number of deaths divided by the expected number of deaths). The expected deaths were based on the white population of Minnesota from 1979 to 2002, recorded by calendar year, sex, age group, and ICD-9- or ICD-10-coded cause of death.<sup>14,16</sup> The  $P$  values to determine differences between time to death among patients in the first 9 deciles compared with the 10th decile were calculated using the test of Gray.<sup>17</sup>

## RESULTS

At baseline, the median age of the community sample of 15,859 individuals was 63 years (range, 50-



**FIGURE 1.** Relationship between the  $\kappa$  and  $\lambda$  free light chain sum ( $\Sigma$  FLC) and the free light chain ratio (rFLC). Most study participants had both normal  $\Sigma$  FLC and rFLC (section v, 86.3%). By definition of light chain monoclonal gammopathy of undetermined significance,<sup>2</sup> no participant had both a high  $\Sigma$  FLC and an abnormal rFLC (low [section iii] or high [section ix]). The distribution of the remaining participants by section was as follows: i, 0.1%; ii, 0.4%; iv, 1.2%; vi, 1.2%; vii, 0.1%; and viii, 0.8%. Blue represents the reference range for  $\Sigma$  FLC (0.95-4.35 mg/dL), yellow represents the reference range for rFLC (0.26-1.65), and green represents those study participants in whom both the  $\Sigma$  FLC and rFLC were normal.



109 years), and 55.3% (n=8753) were women. As of June 2009, median follow-up was 12.7 years (range, 1 day to 14.3 years per person) from sample acquisition, and 4348 individuals (27.4%) had died and had an ICD-coded cause of death. For the purposes of the multivariate analyses, 13,087 individuals (82.5%) had a known creatinine value at the time of their FLC sampling.

#### Prognostic Effect of $\Sigma$ FLC

The  $\Sigma$  FLC was used to study the effect of FLC elevation on survival in persons without evidence of a plasma cell disorder. The relationship between  $\Sigma$  FLC and rFLC is shown in Figure 1; no individual with a high  $\Sigma$  FLC had an abnormal rFLC because these patients were excluded from the study because they were deemed to have LC-MGUS. When  $\Sigma$  FLC

**TABLE 1. Characteristics of Olmsted County, Minnesota, Residents by Decile of  $\Sigma$  FLC<sup>a</sup>**

Characteristic	All residents (N=15,859)	Top decile (n=1581)	Lower 9 deciles (n=14,278)	P value
Age (y)	63 (50-109)	73 (50-109)	62 (50-101)	<.001
Male, No. (%)	7106 (44.8)	782 (49.5)	6324 (44.3)	<.001
Creatinine (mg/dL) <sup>b</sup>	1.0 (0.4-14.2)	1.2 (0.4-14.2)	1.0 (0.4-10.8)	<.001
No. (%) of individuals by creatinine level				
≥1.5 mg/dL	597 (4.5)	355 (25.4)	232 (2.0)	<.001
≥2.0 mg/dL	173 (1.3)	141 (10.1)	32 (0.3)	<.001
$\Sigma$ FLC (mg/dL)	2.8 (0.1-48.2)	5.8 (4.7-48.2)	2.7 (0.1-4.7)	<.001
$\kappa$ FLC (mg/dL)	1.3 (0.01-20.5)	2.8 (1.1-20.5)	1.2 (0.01-2.8)	<.001
$\lambda$ FLC (mg/dL)	1.5 (0.04-28.2)	3.11 (1.8-28.2)	1.4 (0.04-3.6)	<.001
rFLC	0.8 (0.01-40.9)	0.9 (0.3-1.6)	0.8 (0.01-40.9)	<.001

<sup>a</sup>Data are presented as median (range) unless otherwise specified.  $\Sigma$  FLC =  $\kappa$  and  $\lambda$  free light chain sum; FLC = free light chain; rFLC =  $\kappa$  to  $\lambda$  free light chain ratio.

<sup>b</sup>Data available for only 13,087 patients. (To convert to  $\mu\text{mol/L}$ , multiply by 88.4).

**TABLE 2. Risk of Death Among Olmsted County, Minnesota, Residents: Univariate and Multivariate Models<sup>a</sup>**

Term	Risk ratio (95% confidence interval)	P value
Univariate model		
Σ FLC, top decile	4.38 (4.08-4.70)	<.001
Creatinine <sup>b</sup>	1.44 (1.40-1.48)	<.001
Male	1.07 (1.01-1.14)	.02
Age (10-y increase)	3.02 (2.93-3.11)	<.001
Multivariate model		
2 Variables		
Σ FLC, top decile	3.88 (3.59-4.19)	<.001
Creatinine <sup>b</sup>	1.25 (1.21-1.29)	<.001
3 Variables		
Σ FLC, top decile	2.12 (1.96-2.29)	<.001
Creatinine <sup>b</sup>	1.30 (1.25-1.35)	<.001
Age (10-y increase)	2.77 (2.68-2.86)	<.001
4 Variables		
Σ FLC, top decile	2.07 (1.91-2.24)	<.001
Creatinine <sup>b</sup>	1.26 (1.20-1.31)	<.001
Age (10-y increase)	2.85 (2.76-2.95)	<.001
Male sex	1.34 (1.25-1.43)	<.001

<sup>a</sup>Σ FLC = κ and λ free light chain sum.<sup>b</sup>Data available for only 13,087 individuals.**TABLE 3. Observed-to-Expected Risk of Death Among Olmsted County, Minnesota, Residents for Participants With Top Decile Σ FLC<sup>a,b</sup>**

Cause of death by ICD-10 chapter	Observed, No.	Expected, No.	RR	P value
Circulatory	363	168.5	1.9	<.001
Neoplasms	197	96.8	2.0	<.001
Respiratory	80	47.2	1.7	<.001
Mental	68	20.9	3.3	<.001
Nervous system	42	25.6	1.7	<.001
Endocrine	34	18.4	1.6	.02
Genitourinary	31	11.4	2.1	<.001
Digestive	41	13.0	3.0	<.001
External causes	22	11.0	2.1	.001
Injury or poisoning	18	3.4	6.4	<.001
Infectious	16	4.4	3.9	<.001
Skin	3	0.6	5.3	.004
Ill-defined	8	13.7	0.6	.13
Musculoskeletal and connective tissue	7	3.8	1.8	.11
Congenital	2	0.4	5.2	.02
Blood	0	2.1	0.0	.99
Total	932	441.2	2.0	<.001

<sup>a</sup>Σ FLC = κ and λ free light chain sum; ICD-10 = International Statistical Classification of Diseases, 10th Revision (ICD-10); RR = risk ratio.<sup>b</sup>Corrected for age, sex, and serum creatinine level.

was separated into deciles (Figure 2), there was progressively worse survival with increasing values of Σ FLC ( $P<.001$ ). Because the range of Σ FLC was relatively small—0.09 to 48.2 mg/dL—and because the 10th decile (highest Σ FLC) was near the sum of the upper reference ranges for κ FLC and λ FLC, subsequent analyses were collapsed into 2 groups: 10th decile (Σ FLC  $\geq 4.72$  mg/L) vs deciles 1 through 9 (Σ FLC  $< 4.72$  mg/L). As indicated in Table 1, significant differences were found between these 2 groups in terms of mean age (72 vs 62 years;  $P<.001$ ), sex (49.5% [n=782] vs 44.3% [n=6324] male;  $P<.001$ ), and mean serum creatinine level (1.2 vs 1.0 mg/dL;  $P<.001$ ).

On univariate analysis, a Σ FLC result near the upper limit of normal was significantly predictive for worse overall survival (Table 2). The risk ratio for death for those with the highest decile of Σ FLC relative to the other 90% of residents was 4.4 (95% confidence interval, 4.1-4.7). Multivariate analyses, also detailed in Table 2, were performed to exclude the possibility that Σ FLC was merely a surrogate for age, sex, and/or renal insufficiency. With these other variables included, Σ FLC remained a significant independent predictor of worse survival, with a relative risk for death with the highest Σ FLC of 2.1 (95% confidence interval, 1.9-2.2).


### Relationship Between Σ FLC and Cause of Death

We next focused on whether Σ FLC predicted particular causes of death. A total of 4348 Olmsted County residents had an informative death. Table 3 gives the distribution of deaths by cause at the ICD-10 chapter level, with the leading cause of death being circulatory disease (n=363) followed by neoplasms (n=197).

Also indicated in Table 3, the increased mortality in patients with a top decile Σ FLC was not restricted to any specific cause of death. Almost universally, chapter by chapter, those with a higher Σ FLC had a higher risk of death with the exceptions of “blood,” “musculoskeletal/connective tissue,” “genitourinary,” “congenital,” and “ill-defined” conditions. The time from FLC ascertainment to death was also calculated and plotted according to Σ FLC decile (Figure 3). The causes of death most proximal to FLC ascertainment were musculoskeletal, circulatory, neoplasm, respiratory, mental, and digestive disorders.

### DISCUSSION

In this study, we found that a nonclonal elevation of Σ FLC is a significant predictor of worse overall survival in persons without plasma cell disorders. This is a remarkable finding in a general population of individuals 50 years or older who do not have MGUS or LC-MGUS or any other known plasma cell



**FIGURE 3.** Time to death as a function of cause of death and  $\kappa$  and  $\lambda$  free light chain sum ( $\Sigma$  FLC) decile. Time between sample ascertainment to death among 4348 dead Olmsted County residents by *International Statistical Classification of Diseases, 10th Revision (ICD-10)* chapter. Those with the highest  $\Sigma$  FLC deciles died sooner than those with lower (deciles 1-9)  $\Sigma$  FLC deciles. A, Circulatory. B, Neoplasms. C, Respiratory. D, Mental. E, Nervous system. F, Digestive. G, External causes. H, Endocrine. I, Genitourinary. J, Infectious. K, Musculoskeletal. Data for the chapters “ill-defined” and “external causes” are not shown because of small numbers and no significant differences between groups. The red bars represent the 25th, 50th, and 75th percentiles.

disorder. The increased risk of death was independent of renal function, sex, and age. However, the increased risk of death was not restricted to any particular cause of death; the observed-to-expected risk of death from most causes, including cardiac and neoplastic conditions, was significantly higher among individuals with an antecedent  $\Sigma$  FLC equal to or greater than 4.72 mg/dL.

Polyclonal increases in FLC are seen with renal dysfunction; are elevated in diseases such as rheumatoid arthritis, Sjögren syndrome, and systemic lupus erythematosus<sup>18</sup>; and have been shown to be a risk factor for the development of non-Hodgkin

lymphoma among patients with human immunodeficiency virus infection.<sup>7</sup> However, the mechanism by which  $\Sigma$  FLC predicts survival in this large population-based cohort is uncertain. Conditions resulting in overactivation of the immune system may have contributed to the excess risk of death, but inflammatory rheumatologic deaths accounted for less than 1% of all deaths observed in this cohort. However, the observation of a 2-fold risk of cardiovascular death compared with those with lower  $\Sigma$  FLC fits nicely with the emerging connections between inflammation and atherosclerosis.<sup>19</sup> Another possibility is that  $\Sigma$  FLC excess is one manifestation



of immunosenescence, which results in increased susceptibility to infection, malignant neoplasms, and autoimmunity.<sup>20,21</sup>

Our data add to the growing body of literature that connects inflammation, aging, and chronic disease,<sup>21</sup> but they do not provide insight into whether inflammation served as a surrogate for an underlying life-threatening disease entity or whether the underlying inflammation predisposes individuals for conditions such as cancer through free radical-induced injury. Because approximately 20% of all cancers in adults result from chronic inflammatory states or have an inflammatory origin,<sup>22,23</sup> it is not surprising that there was a nearly 2-fold higher observed-to-expected rate of deaths from malignant neoplasms among the patients with high  $\Sigma$  FLC in our cohort. It is intriguing, however, that a  $\Sigma$  FLC measurement taken 3 to 4 years before death has the power to portend a worse outcome for nearly all cause-of-death categories.

Limitations of this study include a lack of other inflammatory markers with which to compare our  $\Sigma$  FLC results and the fact that causes of death were ascertained retrospectively by death certificates. These potential shortcomings are outweighed by the size of the study cohort and its population-based structure, as well as by the simplicity and availability of the FLC assay. Although the FLC assay is able to predict for worse overall survival in an unselected general population, it is not yet clear whether the  $\Sigma$  FLC adds above and beyond other conventional, nonspecific inflammatory markers, such as erythrocyte sedimentation rate or C-reactive protein. However, erythrocyte sedimentation rate and C-reactive protein are acute and chronic inflammatory markers, respectively, rather than markers of the adaptive immune system, which includes highly specialized immune responses. To date, no study has shown such a significant influence with respect to such a breadth of causes of death based on any one assay. Until additional studies are performed on other cohorts with a more expansive inflammatory marker panel, these data are not strong enough to support a recommendation of routine FLC measurement as part of day-to-day clinical practice. Short of that, however, this assay could serve as a means of normalizing the expected risk of death among large patient populations and as a hypothesis-generating tool to study culprits believed to contribute to inflammation, cancer, and aging.

## CONCLUSION

A nonclonal elevation of  $\Sigma$  FLC predicts inferior overall survival in a general population that has been depleted of patients with plasma cell disorders. The observed increased risk of death introduced by a nonclonal elevation of  $\Sigma$  FLC was independent of

renal function, sex, and age and maintained its predictive value regardless of the eventual cause of death.

## ACKNOWLEDGMENTS

We thank Tara Phelps for her maintenance of the peripheral blood sample bank.

**Abbreviations and Acronyms:** FLC = serum immunoglobulin free light chain;  $\Sigma$  FLC =  $\kappa$  and  $\lambda$  free light chain sum; **ICD-9** = *International Classification of Diseases, Ninth Revision*; **ICD-10** = *International Statistical Classification of Diseases, 10th Revision*; **LC-MGUS** = light chain monoclonal gammopathy of undetermined significance; **MGUS** = monoclonal gammopathy of undetermined significance; **rFLC** =  $\kappa$ -to- $\lambda$  FLC ratio

**Grant Support:** This work was supported in part by grants CA62242 (A.D., R.A.K. S.V.R.), CA107476 (A.D., S.V.R., J.A.K., R.A.K.), and CA91561 (A.D.) from the National Cancer Institute, The JABBS Foundation, and The Predolin Foundation. Binding Site provided the serum immunoglobulin free light chain reagent. This study was supported in part by National Institutes of Health grant R01 AG034676 and the Rochester Epidemiology Project (grant number R01-AG034676; Principal Investigator: Walter A. Rocca, MD).

**Potential Competing Interests:** Drs Dispenzieri and Katzmman have received a travel grant from Binding Site, to present data. Dr Mead is an employee of Binding Site. Free light chain reagent was provided by Binding Site. There are no other potential conflicts of interest.

**Correspondence:** Address to Angela Dispenzieri, MD, Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905 (dispenzieri.angela@mayo.edu).

## REFERENCES

1. Dispenzieri A, Kyle R, Merlini G, et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. *Leukemia*. 2009; 23(2):215-224.
2. Dispenzieri A, Katzmman JA, Kyle RA, et al. Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. *Lancet*. 2010;375(9727):1721-1728.
3. Pratt G, Harding S, Holder R, et al. Abnormal serum free light chain ratios are associated with poor survival and may reflect biological subgroups in patients with chronic lymphocytic leukaemia. *Br J Haematol*. 2009;144(2):217-222.
4. Yegin ZA, Ozkurt ZN, Yağci M. Free light chain: a novel predictor of adverse outcome in chronic lymphocytic leukaemia. *Eur J Haematol*. 2010;84(5):406-411.
5. Maurer MJ, Micallef IN, Cerhan JR, et al. Elevated serum free light chains are associated with event-free and overall survival in two independent cohorts of patients with diffuse large B-cell lymphoma. *J Clin Oncol*. 2011;29(12):1620-1626.
6. Dispenzieri A, Lacy MQ, Katzmman JA, et al. Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. *Blood*. 2006;107(8):3378-3383.

7. Landgren O, Goedert JJ, Rabkin CS, et al. Circulating serum free light chains as predictive markers of AIDS-related lymphoma. *J Clin Oncol*. 2010;28(5):773-779.
8. Kyle RA, Therneau TM, Rajkumar SV, et al. Prevalence of monoclonal gammopathy of undetermined significance. *N Engl J Med*. 2006;354(13):1362-1369.
9. Rajkumar SV, Kyle RA, Therneau TM, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. *Blood*. 2005;106(3):812-817.
10. Melton LJ III. The threat to medical-records research. *N Engl J Med*. 1997;337(20):1466-1470.
11. St Sauver JL, Grossardt BR, Yawn BP, Melton LJ III, Rocca WA. Use of a medical records linkage system to enumerate a dynamic population over time: the Rochester Epidemiology Project. *Am J Epidemiol*. 2011;173(9):1059-1068.
12. Melton LJ III. History of the Rochester Epidemiology Project. *Mayo Clin Proc*. 1996;71(3):266-274.
13. Katzmann JA, Clark RJ, Abraham RS, et al. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. *Clin Chem*. 2002;48(9):1437-1444.
14. Compressed Mortality File (CMF), 1989-1998. [http://www.cdc.gov/nchs/data\\_access/cmf.htm](http://www.cdc.gov/nchs/data_access/cmf.htm). Accessed May 3, 2012.
15. Gail MH, Byar DP. Variance calculations for direct adjusted survival curves, with applications to testing for no treatment effect. *Biometric J*. 1986;28:587-599.
16. Compressed Mortality File (CMF), 1999-2002. [http://www.cdc.gov/nchs/data\\_access/cmf.htm](http://www.cdc.gov/nchs/data_access/cmf.htm). Accessed May 3, 2012.
17. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. *Ann Stat*. 1988;16:1141-1154.
18. Gottenberg JE, Aucouturier F, Goetz J, et al. Serum immunoglobulin free light chain assessment in rheumatoid arthritis and primary Sjogren's syndrome. *Ann Rheum Dis*. 2007;66(1):23-27.
19. Puntmann VO, Taylor PC, Mayr M. Coupling vascular and myocardial inflammatory injury into a common phenotype of cardiovascular dysfunction: systemic inflammation and aging—a mini-review. *Gerontology*. 2011;57(4):295-303.
20. Busse PJ, Mathur SK. Age-related changes in immune function: effect on airway inflammation. *J Allergy Clin Immunol*. 2010;126(4):690-700.
21. Ahmad A, Banerjee S, Wang Z, Kong D, Majumdar AP, Sarkar FH. Aging and inflammation: etiological culprits of cancer. *Curr Aging Sci*. 2009;2(3):174-186.
22. Lu H, Ouyang W, Huang C. Inflammation, a key event in cancer development. *Mol Cancer Res*. 2006;4(4):221-233.
23. Coussens LM, Werb Z. Inflammation and cancer. *Nature*. 2002;420(6917):860-867.